Shares in longevity-focused Genflow Biosciences jumped on Monday after the company outlined plans to to accelerate drug discovery through the use of an AI-powered platform.
Genflow Biosciences, Europe’s sole publicly listed longevity company, has established a strategic alliance with American AI specialists Heureka Labs, providing access to Heureka’s sophisticated artificial intelligence platform.
Developed as a technology spin-off from Duke University, Heureka’s system specialises in analysing complex genomic data, including RNA sequencing and gene expression profiles.
The implementation of Heureka’s AI technology will substantially enhance GenFlow’s ability to interpret intricate biological datasets, yielding deeper insights into gene regulatory networks and systemic biological responses. These capabilities are crucial for optimising therapeutic design and predicting patient-specific outcomes, with Genflow maintaining all intellectual property rights under the agreement.
While there are no obvious limitations to the partnership and the scope of their work together, the initial focus of this partnership will support Genflow’s lead candidate, GF-1002, a centenarian SIRT6-based gene therapy currently undergoing preclinical evaluation. The collaboration may subsequently extend to additional pipeline gene therapy programmes, including treatments targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Heureka’s AI platform, already utilised by leading pharmaceutical and biotechnology firms, is engineered to accelerate drug discovery by generating testable hypotheses, identifying unexpected biological patterns, and streamlining research and development workflow.
“Incorporating AI is no longer optional in bioinformatics research-it’s essential for precision, speed, and scale,” said Dr. Eric Leire, CEO of Genflow.
“Heureka’s AI platform gives us the tools to navigate complex biological data and refine our gene therapy approach across a number of programs we are working on, accelerating the delivery of safe and effective therapies that promote a healthier lifespan, while helping to ease the growing operational and economic burden of an aging population.”
Genflow Biosciences shares were 12% higher at the time of writing.